- Global News Feed
- Alabama Stem Cells
- Alaska Stem Cells
- Arkansas Stem Cells
- Arizona Stem Cells
- California Stem Cells
- Colorado Stem Cells
- Connecticut Stem Cells
- Delaware Stem Cells
- Florida Stem Cells
- Georgia Stem Cells
- Hawaii Stem Cells
- Idaho Stem Cells
- Illinois Stem Cells
- Indiana Stem Cells
- Iowa Stem Cells
- Kansas Stem Cells
- Kentucky Stem Cells
- Louisiana Stem Cells
- Maine Stem Cells
- Maryland Stem Cells
- Massachusetts Stem Cells
- Michigan Stem Cells
- Minnesota Stem Cells
- Mississippi Stem Cells
- Missouri Stem Cells
- Montana Stem Cells
- Nebraska Stem Cells
- New Hampshire Stem Cells
- New Jersey Stem Cells
- New Mexico Stem Cells
- New York Stem Cells
- Nevada Stem Cells
- North Carolina Stem Cells
- North Dakota Stem Cells
- Oklahoma Stem Cells
- Ohio Stem Cells
- Oregon Stem Cells
- Pennsylvania Stem Cells
- Rhode Island Stem Cells
- South Carolina Stem Cells
- South Dakota Stem Cells
- Tennessee Stem Cells
- Texas Stem Cells
- Utah Stem Cells
- Vermont Stem Cells
- Virginia Stem Cells
- Washington Stem Cells
- West Virginia Stem Cells
- Wisconsin Stem Cells
- Wyoming Stem Cells
- Cell Medicine
- Cell Therapy
- Gene therapy
- Genetic Engineering
- Genetic medicine
- HCG Diet
- Hormone Replacement Therapy
- Human Genetics
- Integrative Medicine
- Molecular Genetics
- Molecular Medicine
- Nano medicine
- Preventative Medicine
- Regenerative Medicine
- Stem Cells
- Stell Cell Genetics
- Stem Cell Research
- Stem Cell Treatments
- Stem Cell Therapy
- Stem Cell Videos
- Testosterone Replacement Therapy
- Testosterone Shots
Category Archives: Biotechnology
Biotechnology Market 2021 Covering Impact of COVID-19 and SWOT Analysis by Global Top Companies UNLV The Rebel Yell – UNLV The Rebel Yell
Posted: August 31, 2021 at 2:09 am
Polaris Market Research has released the latest research report on the Biotechnology Market. The report is a comprehensive numerical analysis of the market and provides data to formulate strategies to improve the growth and success of the market. This Biotechnology market report provides a detailed assessment of the market highlighting different aspects such as drivers, trends, opportunities, restraints, and challenges.
This comprehensive Biotechnology market research report utilizes effective and advanced tools and techniques including SWOT analysis and Porters five forces analysis. Market reports help strengthen the organization and make better decisions to keep the business on track. This report is a compilation of comprehensive research into all aspects of the Biotechnology Market. With accurate data and highly authentic information, it has made a wonderful attempt to provide a true and transparent picture of current and future conditions in the Biotechnology market.
Get FREE sample copy of the report : https://www.polarismarketresearch.com/industry-analysis/biotechnology-market/request-for-sample
This Report Sample Includes:
The competition model in Biotechnology market provides detailed information by the competitors. Detailed information includes company profile, company finances, revenue generated, market potential, R&D investments, new market plans, regional presence, strengths and weaknesses of the company. company, product launch, product width and breadth, and application advantages.
Some well-established players in the Biotechnology market are
Agilent Technologies, BioGen Medical Instruments, Danaher, F. Hoffmann-La Roche, Abbott Laboratories Illumina, Merck, PerkinElmer, Qiagen and Thermo Fisher Scientific, Amgen, Bio-Rad Laboratories
MARKET SEGMENTATION :
The report has conducted extensive research on the market segments and sub-segments and made it clear which market segment will dominate the market during the forecast period. In order to help clients to make informed decisions about business investment plans and strategies in the Biotechnology market, report provides detailed information regarding regional market performance and competitor analysis.
Segmentation by type: Type 1, Type 2
Segmentation by application: application 1, application 2
(Details in Sample Report, Download sample copy at FREE of cost)
Key points of the geographic analysis:
Ask For Discount Before Purchasing This Business Report @ https://www.polarismarketresearch.com/industry-analysis/biotechnology-market/request-for-discount-pricing
The latest business intelligence report analyzes the market in terms of market reach and customer base in key geographic market regions. The Biotechnology market can be geographically divided into:
Key questions answered in this report
If You Have Any Query, Ask Our Experts @ https://www.polarismarketresearch.com/industry-analysis/biotechnology-market/speak-to-analyst
Thanks for reading this article; you can also get individual chapter wise section or region wise report version like North America, Europe or Asia.
Corporate Sales, USA
Polaris market Research
Posted: at 2:09 am
PHILADELPHIA, Aug. 30, 2021 (GLOBE NEWSWIRE) -- AnPac Bio-Medical Science Co., Ltd. (AnPac Bio, the Company or we) (NASDAQ: ANPC), a biotechnology company with operations in the United States and China, today announced that its Philadelphia, PA Clinical Laboratory Improvement Amendments (CLIA) certified laboratory has received accreditation from the College of American Pathologists (CAP). The U.S. federal government recognizes the CAP Laboratory Accreditation Program, begun in the early 1960s, as being equal-to or more-stringent-than the governments own inspection program. During the CAP accreditation process, designed to ensure the highest standard of care for all laboratory results, inspectors examine the laboratorys records and quality control of the procedures for the preceding two years. CAP inspectors also examine laboratory staff qualifications, equipment, facilities, safety program and records, and overall management.
Anpac Bio is proud to have received this accreditation, said Dr. Pandit, the CLIA Laboratory director and CEO of Anpac Bio in the United States. The College of American Pathologists (CAP) is the gold standard in medical laboratory accreditation. Through this rigorous inspection process, CAP has certified that Anpac Bio is meeting the highest standards in quality patient care. We have strived from the beginning to lead the industry in quality and innovation. CAP certification is a major milestone along our journey to deliver on our promise of ground-breaking science and commercialization for our novel cancer differentiation analysis (CDA) technology in the United States. We know that the CAP accreditation will only communicate further to our clients, research partners, and future patients, that Anpac Bio is committed to excellence and exceptional laboratory processes.
Dr. Chris Yu, CEO and Chairman of AnPac Bio commented: AnPac Bio is proud to join an outstanding group of select laboratories globally that have received this accreditation. With the CAP accreditation of our Philadelphia laboratory, we have now consolidated our California laboratory into one single expanded ultramodern facility in the USA. The CAP Accreditation for our Philadelphia facility demonstrates that our laboratory operates at the highest standards and is another key step in delivering on our mission to detect cancer early through the power of our CDA technology.
About the College of American Pathologists
As the worlds largest organization of board-certified pathologists and leading provider of laboratory accreditation and proficiency testing programs, the College of American Pathologists (CAP) serves patients, pathologists, and the public by fostering and advocating excellence in the practice of pathology and laboratory medicine worldwide.
About AnPac Bio
AnPac Bio is a biotechnology company focused on early cancer screening and detection, with 142 issued patents as ofMarch 31, 2021. With one CLIA- and CAP-registered clinical laboratory inthe United Statesand two certified clinical laboratories inChina, AnPac Bio performs a suite of cancer screening and detection tests, including CDA (Cancer Differentiation Analysis), biochemical, immunological and genomics tests. According to a Frost & Sullivans report issued in 2020, AnPac Bio ranked third worldwide among companies offering next-generation early cancer screening and detection technologies in terms of the number of clinical samples for cancer screening and detection in 2019. The Company has a significant cancer screening and detection database consisting of approximately 43,900 clinical samples as ofMarch 31, 2021. AnPac Bios CDA technology platform has been shown in retrospective validation studies to be able to detect the risk of over 20 different cancer types with high sensitivity and specificity.
For more information, please visit: https://www.Anpacbio.com.
For investor and media inquiries, please contact:
Company:Phil Case, Marketing and Investor RelationsPhone: +1-267-810-6776 (US)Email:phil_case@AnPacbio.com
Investor Relations:Ascent Investor Relations LLCTina Xiao, PresidentPhone: +1-917-609-0333 (US)Email:firstname.lastname@example.org
Safe Harbor Statement
This announcement contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. These forward-looking statements are made under the safe harbor provisions of the Private Securities Litigation Reform Act of 1995 and are relating to the Companys future financial and operating performance. The Company has attempted to identify forward-looking statements by terminologies including believes, estimates, anticipates, expects, plans, projects, intends, potential, target, aim, predict, outlook, seek, goal objective, assume, contemplate, continue, positioned, forecast, likely, may, could, might, will, should, approximately or other words that convey uncertainty of future events or outcomes to identify these forward-looking statements. These statements are based on current expectations, assumptions and uncertainties involving judgments about, among other things, future economic, competitive and market conditions and future business decisions, all of which are difficult or impossible to predict accurately and many of which are beyond the Companys control. These statements also involve known and unknown risks, uncertainties and other factors that may cause the Companys actual results to be materially different from those expressed or implied by any forward-looking statement. Known and unknown risks, uncertainties and other factors include, but are not limited to, the implementation of our business model and growth strategies; trends and competition in the cancer screening and detection market; our expectations regarding demand for and market acceptance of our cancer screening and detection tests and our ability to expand our customer base; our ability to obtain and maintain intellectual property protections for our CDA technology and our continued research and development to keep pace with technology developments; our ability to obtain and maintain regulatory approvals from the NMPA, the FDA and the relevant U.S. states and have our laboratories certified or accredited by authorities including the CLIA; our future business development, financial condition and results of operations and our ability to obtain financing cost-effectively; potential changes of government regulations; general economic and business conditions in China and elsewhere; our ability to hire and maintain key personnel; our relationship with our major business partners and customers; and the duration of the coronavirus outbreaks and their potential adverse impact on the economic conditions and financial markets and our business and financial performance, such as resulting from reduced commercial activities due to quarantines and travel restrictions instituted by China, the U.S. and many other countries around the world to contain the spread of the virus. Additionally, all forward-looking statements are subject to the Risk Factors detailed from time to time in the Companys most recent Annual Report on Form 20-F and other filings with the U.S. Securities and Exchange Commission. Because of these and other risks, uncertainties and assumptions, undue reliance should not be placed on these forward-looking statements. In addition, these statements speak only as of the date of this press release and, except as may be required by law, the Company undertakes no obligation to revise or update publicly any forward-looking statements for any reason.
See the rest here:
AnPac Bio's USA Laboratory Receives Accreditation from the - GlobeNewswire
Posted: at 2:09 am
The analyst presents post-COVID-19 growth opportunities and strategic imperatives for the global drug discovery and early development outsourcing market in this study, which covers research and development (R&D) efforts, market trends, key participants, drivers and restraints of market adoption, and recent mergers and acquisitions.
New York, Aug. 30, 2021 (GLOBE NEWSWIRE) -- Reportlinker.com announces the release of the report "Global Drug Discovery and Early Development Outsourcing Growth Opportunities" - https://www.reportlinker.com/p06130908/?utm_source=GNW The report identifies the evolving competitive landscape and initiatives taken by key contract research organizations (CRO) and contract development and manufacturing organizations (CDMO) to adapt to the growing needs of pharmaceutical and biotechnology sponsors. The drug discovery and early development outsourcing market was worth $19.65 billion in 2020 and is estimated to grow at a compound annual growth rate of 6.4% up to 2026, with North America continuing to lead the market. In terms of overall R&D expenditure, the contribution of large pharmaceutical companies is steadily declining due to their focus on leaner portfolios. In contrast, the contribution of emerging biotechnology companies to drug development has grown more than 80% since 2018. Pharmaceutical companies are directing their R&D spending mainly toward strengthening their oncology portfolio and increasing year-on-year acquisitions of clinical-stage biopharmaceutical companies focusing on oncology therapy, suggesting both the potential of new technologies and promising returns on investment for these assets. Leading CROs and CDMOs are also focused on oncology, with anticancer drugs reportedly contributing the highest to the drug development pipeline in 2020. COVID-19-related drug discovery and early development research is projected to slow down in 2022 as most projects would have advanced to the clinical research stage by then. When pandemic-related restrictions are lifted, a surge in outsourcing for the next two years is expected as companies resume their non-COVID-19 drug discovery programs that were stalled during the pandemic.In the United States and Europe, testing service providers with best-in-class good laboratory practices (GLP) and good track records are the preferred partner for completing investigational new drugsenabling studies. Global CROs may have in-house capabilities, but pharmaceutical companies still prefer independent validation from specialists to minimize the risk of failure early on in the development life cycle before moving toward regulatory filing. Key industry participants are positioning themselves to be end-to-end integrated service providers for pharmaceutical and biotechnology sponsors. The growing demand for end-to-end integrated drug discovery and development support is closing the gap that distinguishes a CRO from a CDMO. The promise of artificial intelligence in drug discovery, along with novel approaches to target undruggable RNA, is set to drive small molecule drug discovery and outsourcing while the growth in biologics is expected to boost the need for better disease models and advanced in vivo pharmacology capabilities. Exploring novel expression systems to support the urgent needs of infectious disease management is also forecast to gain momentum especially as the industry favors single-use reactors for future biotherapeutics. Author: Meghna Hiren ThakkarRead the full report: https://www.reportlinker.com/p06130908/?utm_source=GNW
About ReportlinkerReportLinker is an award-winning market research solution. Reportlinker finds and organizes the latest industry data so you get all the market research you need - instantly, in one place.
Read the original post:
Global Drug Discovery and Early Development Outsourcing Growth Opportunities - Yahoo Finance
Agathos Biologics Receives $900,000 from the North Dakota Bioscience Innovation Grant Program – BioSpace
Posted: at 2:09 am
FARGO, N.D.--(BUSINESS WIRE)-- Agathos Biologics, a biotechnology company developing transformational science within a strong ethical and moral framework, today announced the company has been awarded $900,000 from the North Dakota Department of Agriculture Bioscience Innovation Grant (BIG) Program. Agriculture Commissioner Doug Goehring announced that nine grants have been awarded totaling $4.9 million to foster the growth of the bioscience industry in North Dakota. Advances in bioscience have already transformed many sectors including agriculture and medicine, Goehring said. These grants will help North Dakota stay on the forefront of bioscience innovation.
Agathos Biologics project funded by ND BIG will focus on challenges that limit patient access to advanced genetic medicines that can significantly impact quality of lifecost, availability, and ethical concerns. Company scientists will create new materials and methods for research and biomanufacturing and use them for drug development, which will address unmet medical needs and increase the availability of genetic medicines to more patients. The company will make these products and services available to the broader biotechnology industry through direct sales and licensing, partnerships, and collaborations.
We are honored to receive this support from the State of North Dakota and thank the Commissioner and the Committee for their work on behalf of the citizens of the state, said James Brown, Chief Executive Officer of Agathos Biologics. We founded the company in North Dakota because its business-friendly environment, skilled workforce, and growing biotechnology ecosystem make it an ideal place to expand the company and achieve our goal to develop genetic medicine products and services that positively impact human health and are ethically acceptable to all.
About Agathos Biologics
Agathos Biologics is a biotechnology company pursuing transformational science in biomanufacturing, biologic payload delivery, and cell and gene therapy. Discoveries in bioprocessing and genetic characterization and control have created an abundance of scientific possibilities that can help us all lead better lives. Our mission as the good science company is to create breakthrough products and services within a strong ethical and moral framework that benefits everyone. We believe in science that serves and have a relentless focus on serving our clients, employees, and society. For more information, please visit http://www.agathos.bio.
View source version on businesswire.com: https://www.businesswire.com/news/home/20210830005432/en/
Go here to see the original:
Agathos Biologics Receives $900,000 from the North Dakota Bioscience Innovation Grant Program - BioSpace
[PDF] White Biotechnology Market size and Generated Opportunities of volume and value UNLV The Rebel Yell – UNLV The Rebel Yell
Posted: at 2:09 am
White bio-technology is widely used in manufacture of bio-fuels, bio-materials, and bio-chemicals. Examples of bio-chemicals include levulenic acid, butanediol, succinic acid, acrylic acid, and lactic acid. Generally, bio-fuels are prepared from carbohydrates of starch and sugar crops. Some of the bio-materials are bio-plastics and bio-polymers.
By 2027, the global white biotechnology market is forecasted to have a market capital of US$ 299.9 billion.
FREE | Request Sample is Available @https://www.coherentmarketinsights.com/insight/request-sample/3876
*The Sample only consist ofTable of Content (ToC).Research Frameworkof the actual report.Research Methodologyadopted for it.
Major Company Profiles Covered in This Report:Archer Daniels Midland Company, BASF SE, Cargill, Inc., Corbion N.V., Koninklijke DSM N.V, DuPont, Lesaffre, Novozymes, Fujifilm Holdings Corporation, GE Healthcare, Hitachi Medical Corporation, Hologic, Inc., iCAD, Inc., InVivo Corporation, McKesson Corporation, Merge Healthcare Incorporated (IBM), Philips Healthcare, Samsung Medison Co. Ltd., Siemens Healthcare, and Toshiba Medical Systems Corporation.
Rising adoption of bio-materials in the healthcare industry is expected to stimulate growth of the global white biotechnology market during the forecast period. In October 2019, German researchers from Institute of Pharmacology and Toxicology, had reported that marine bio-materials which are pre-fabricated naturally, can help in preparing a new sponge chitin-based absorbable hemostats as a substitute for cellulose-based fabrics.
Rising demand for organic food across the globe is expected to provide robust growth opportunities for companies operating in the global white biotechnology market. As per the Organic Industry Survey done by the Organic Trade Association, in 2018, the sales of organic food had increased by 5.9% to attain about US$ 47.9 billion in the U.S., and these sales accounted for 5.7% of overall food sales, a 2.3% hike from 2017.
High cost associated with bio-products as compared to traditional products is expected to obstruct growth of the global white biotechnology market. Polyactic acid can be priced about 20 to 50% more than the traditional materials. Higher cost of bio-products is due to its complex production.
Request Free research report Brochure @https://www.coherentmarketinsights.com/insight/request-pdf/3876
During the forecast period (2020-2027), the global white biotechnology market had a valuation of US$ 207.5 billion in 2019 and is anticipated to attain a capital of US$ 299.9 billion by 2027 with a CAGR of 4.7%. Increased adoption of bio-materials in the healthcare industry is expected to augment growth of the global white biotechnology market during the forecast period.
In 2019, the Bio-fuel segment held a commanding position in the global white biotechnology market, contributing about 34.7% of market share, which was followed by Bio-chemical and Bio-material segments, respectively. Increase in investment for production of bio-fuels along with adoption of collaborative strategies among key players in the market.
Companies operating in the market are having a focus on bio-diesels real-world efficacy. In February 2020, the Archer Daniels Midland Company under a collaboration for conducting a one-year project of bio-diesel technology in order to achieve fleet application of higher mileage, had declared that five trucks of the company were going to be outfitted with a technology which will allow diesel engines to operate on sustainable biodiesel, Optimus Technologies Vector fuel system.
The focus of key companies in the market on adopting merger and acquisition strategies to broaden their portfolio of products. In September 2019, BASF SE had acquired Isobionics, a natural fragrances and flavors provider.
Inquire more about this report @ https://www.coherentmarketinsights.com/insight/talk-to-analyst/3876
Some Notable Offerings by Coherent Market Insights Report on White Biotechnology market:
We will provide you an analysis of the extent to which this White Biotechnology market research report acquires commercial characteristics along with examples or instances of information that helps you to understand it better.
We will also help to identify customary/ standard terms and conditions, as offers, worthiness, warranty, and others.
Also, this report will help you to identify any trends to forecast growth rates.
The analyzed report will forecast the general tendency for supply and demand.
How Coherent Market Insights Assists in Making Strategic Moves For White Biotechnology Market Manufacturer?
The data provided in the White Biotechnology market report offers comprehensive analysis of important industry trends. Industry players can use this data to strategize their potential business moves and gain remarkable revenues in the upcoming period.
The report covers the price trend analysis and value chain analysis along with analysis of diverse offering by market players. The main motive of this report is to assist enterprises to make data-driven decisions and strategize their business moves.
Also, Research Report Examines:
Competitive companies and manufacturers in global market
By Product Type, Applications & Growth Factors
Industry Status and Outlook for Major Applications / End Users / Usage Area
Thanks for reading this article; you can also get individual chapter wise section or region wise report version like North America, Europe or Asia.
As Unity Biotechnology, Inc.’s (NASDAQ:UBX)) market cap dropped by US$27m, insiders who sold US$8.9m worth of stock were able to offset their losses -…
Posted: August 18, 2021 at 2:05 am
Insiders seem to have made the most of their holdings by selling US$8.9m worth of Unity Biotechnology, Inc. (NASDAQ:UBX) stock at an average sell price of US$5.24 during the past year. The companys market cap plunged by US$27m after price dropped by 13% last week but insiders were able to limit their loss to an extent.
While we would never suggest that investors should base their decisions solely on what the directors of a company have been doing, we do think it is perfectly logical to keep tabs on what insiders are doing.
See our latest analysis for Unity Biotechnology
The Co-Founder & Executive Director, Nathaniel David, made the biggest insider sale in the last 12 months. That single transaction was for US$8.9m worth of shares at a price of US$5.24 each. While we don't usually like to see insider selling, it's more concerning if the sales take place at a lower price. The silver lining is that this sell-down took place above the latest price (US$3.31). So it may not tell us anything about how insiders feel about the current share price. The only individual insider seller over the last year was Nathaniel David.
The chart below shows insider transactions (by companies and individuals) over the last year. By clicking on the graph below, you can see the precise details of each insider transaction!
For those who like to find winning investments this free list of growing companies with recent insider purchasing, could be just the ticket.
For a common shareholder, it is worth checking how many shares are held by company insiders. I reckon it's a good sign if insiders own a significant number of shares in the company. Insiders own 3.6% of Unity Biotechnology shares, worth about US$6.5m, according to our data. Whilst better than nothing, we're not overly impressed by these holdings.
There haven't been any insider transactions in the last three months -- that doesn't mean much. Our analysis of Unity Biotechnology insider transactions leaves us unenthusiastic. And usually insiders own more stock in the company, according to our data. While we like knowing what's going on with the insider's ownership and transactions, we make sure to also consider what risks are facing a stock before making any investment decision. To help with this, we've discovered 5 warning signs (2 are significant!) that you ought to be aware of before buying any shares in Unity Biotechnology.
If you would prefer to check out another company -- one with potentially superior financials -- then do not miss this free list of interesting companies, that have HIGH return on equity and low debt.
For the purposes of this article, insiders are those individuals who report their transactions to the relevant regulatory body. We currently account for open market transactions and private dispositions, but not derivative transactions.
When trading Unity Biotechnology or any other investment, use the platform considered by many to be the Professional's Gateway to the Worlds Market, Interactive Brokers. You get the lowest-cost* trading on stocks, options, futures, forex, bonds and funds worldwide from a single integrated account. Promoted
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned. *Interactive Brokers Rated Lowest Cost Broker by StockBrokers.com Annual Online Review 2020
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.
Posted: at 2:05 am
When Tara Cameron decided she wanted to transition from her career as a certified nursing assistant into a new position in the medical field, she turned to colleagues and friends. Overwhelmingly, they recommended she check out Wake Techs BioWork certificate program.
Today, her career looks different than it did 20 years ago, but as a downstream, or purification, technician at FUJIFILM Diosynth Biotechnologies in Morrisville, she has stayed true to her healthcare roots.
Working with my elderly residents day-to-day, I saw the importance of medicine in their lives, said Cameron. When I decided to change careers, I knew I wanted to stay in healthcare. My friends and colleagues talked a lot about the programs at Wake Tech, which is where I learned about the BioWork program and jobs in biomanufacturing.
The BioWork certificate is earned through a 12-week program offered at 11 community colleges across the state. The program teaches students the foundational skills for a career as a process technician for biotechnology, pharmaceutical or chemical manufacturing companies.
The part of the program Cameron enjoyed the most was learning about the importance of standard operating procedures (commonly referred to as SOPs in the biopharmaceutical industry).
I enjoyed working in the lab the most, said Cameron. This is where I learned about SOPs. They are similar to a recipe that you need to follow step-by-step.
Today as a downstream tech at FUJIFILM Diosynth, Cameron is part of the biomanufacturing team responsible for the purification of biological molecules such as recombinant proteins, using filtration and chromatography.
This is not her first position in biomanufacturing, however. Prior to her current position, she had also gained on-the-job experience at Merck.
At Wake Tech, students are filling up the BioWork certificate courses. According to its website, all BioWork courses for the fall semester are full, but the school is in the process of hiring an additional instructor.
According to Mike Morgan, Wake Techs workforce continuing education BioWork program director, 180 students receive the certificate each year.
In addition to offering the certificate program, the school holds in-person and virtual job fairs to connect students with life science and staffing companies.
Since the COVID-19 pandemic hit in March of 2020, we have had very successful virtual career fairs organized by NC BioNetwork, said Morgan. We have been doing one of these each spring, summer and fall since April 2020.
For her part, Cameron recommends those interested in making a career change check out the program.
I would tell others to try the BioWork program because there are vast opportunities, and the pays is very competitive, she said. You can always find a job.
Read the rest here:
Mother Finds New Career Thanks to BioWork Program - ncbiotech.org
UNITY Biotechnology, Inc. to Participate in the HC Wainwright Ophthalmology Virtual Conference – GlobeNewswire
Posted: at 2:05 am
SOUTH SAN FRANCISCO, Calif., Aug. 16, 2021 (GLOBE NEWSWIRE) -- UNITY Biotechnology, Inc. (UNITY) [NASDAQ:UBX], a biotechnology company developing therapeutics to slow, halt, or reverse diseases of aging, today announced that members of its senior management team will present at the upcoming H.C. Wainwright Ophthalmology Virtual Conference.
H.C. Wainwright Ophthalmology Virtual ConferenceDate:Tuesday, August 17, 2021 On-Demand Presentation Available:7:00 a.m. ET
As part of the event Anirvan Ghosh, Ph.D., chief executive officer of UNITY, will participate in the panel titled, Vision Repair Beyond Traditional Anti-VEGF Therapy What Does the Future Hold? hosted by Matthew Caufield, equity research analyst at H.C. Wainwright. To register for the event, please visit the conference website here.
A live audio webcast of the corporate presentation will be available through the Investors & Media section of UNITYs website here. An archived replay will be available for 90 days following the event.
About UNITYUNITY is developing a new class of therapeutics to slow, halt, or reverse diseases of aging. UNITYs current focus is on creating medicines to selectively eliminate or modulate senescent cells and thereby provide transformative benefit inage-relatedophthalmologic and neurologic diseases. More information is available atwww.unitybiotechnology.comor follow us onTwitter and LinkedIn.
Forward-Looking StatementsThis press release contains forward-looking statements including statements related to UNITYs understanding of cellular senescence and the role it plays in diseases of aging, the potential for UNITY to develop therapeutics to slow, halt, or reverse diseases of aging, including for ophthalmologic and neurologic diseases, our expectations regarding potential benefits, activity, effectiveness, and safety of UBX1325, the potential for UNITY to successfully commence and complete clinical studies of UBX1325 for DME, AMD, and other ophthalmologic diseases, the expected timing of results of our studies of UBX1325, the timing of the expected commencement, progression, and conclusion of our studies including those of UBX1325, and UNITYs expectations regarding the sufficiency of its cash runway. These statements involve substantial known and unknown risks, uncertainties, and other factors that may cause our actual results, levels of activity, performance, or achievements to be materially different from the information expressed or implied by these forward-looking statements, including the risk that theCOVID-19worldwide pandemic may continue to negatively impact the development of preclinical and clinical drug candidates, including delaying or disrupting the enrollment of patients in clinical trials, risks relating to the uncertainties inherent in the drug development process, and risks relating to UNITYs understanding of senescence biology. We may not actually achieve the plans, intentions, or expectations disclosed in our forward-looking statements, and you should not place undue reliance on our forward-looking statements. Actual results or events could differ materially from the plans, intentions, and expectations disclosed in the forward-looking statements we make. The forward-looking statements in this press release represent our views as of the date of this release. We anticipate that subsequent events and developments will cause our views to change. However, while we may elect to update these forward-looking statements at some point in the future, we have no current intention of doing so except to the extent required by applicable law. You should, therefore, not rely on these forward-looking statements as representing our views as of any date subsequent to the date of this release.For a further description of the risks and uncertainties that could cause actual results to differ from those expressed in these forward-looking statements, as well as risks relating to the business of UNITY in general, see UNITYs most recent Quarterly Report on Form 10-Q for the quarter endedJune 30, 2021, filed with theSecurities and Exchange Commissionon August 10, 2021, as well as other documents that may be filed by UNITY from time to time with theSecurities and Exchange Commission.
The Securities and Exchange Commission Declared Cellect Biotechnologys Registration Statement Filed on Form F-4 Effective in Connection with its…
Posted: at 2:05 am
Special General Meeting of Shareholders Scheduled for September 19, 2021
Tel Aviv, Israel, Aug. 13, 2021 (GLOBE NEWSWIRE) -- Cellect Biotechnology Ltd. (NASDAQ: "APOP"), a developer of innovative technology that enables the functional selection of stem cells, announced that its registration statement filed on Form F-4 with Securities and Exchange Commission (SEC) on August 10, 2021 was declared effective by the SEC on August 12, 2021 (the Form F-4). The Form F-4 was filed in connection with the previously announced strategic merger with Quoin Pharmaceuticals, Inc., a privately held U.S. based company focused on rare and orphan diseases.
The Company has scheduled a Special General Meeting of Shareholders for September 19, 2021, and anticipates closing the transaction by September 30, 2021, subject to completion of previously disclosed closing conditions and approvals contained in the merger agreement.
Additional information regarding the proposed strategic merger can be found in the Form F-4.
About Cellect Biotechnology Ltd.
Cellect Biotechnology (APOP) has developed a breakthrough technology for the selection of stem cells from any given tissue that aims to improve a variety of cell-based therapies.
The Company's products are expected to provide researchers, clinicians and pharmaceutical companies with the tools to rapidly isolate specific cells in quantity and quality, allowing cell-based treatments and procedures in a wide variety of applications in regenerative medicine. The Company's lead product is currently in FDA approved clinical trial is aimed at bone marrow transplantations in cancer treatment.
Forward Looking Statements This press release contains forward-looking statements about the Company's expectations, beliefs and intentions. Forward-looking statements can be identified by the use of forward-looking words such as "believe", "expect", "intend", "plan", "may", "should", "could", "might", "seek", "target", "will", "project", "forecast", "continue" or "anticipate" or their negatives or variations of these words or other comparable words or by the fact that these statements do not relate strictly to historical matters. These forward-looking statements and their implications are based on the current expectations of the management of the Company only and are subject to a number of factors and uncertainties that could cause actual results to differ materially from those described in the forward-looking statements. In addition, historical results or conclusions from scientific research and clinical studies do not guarantee that future results would suggest similar conclusions or that historical results referred to herein would be interpreted similarly in light of additional research or otherwise. The following factors, among others, could cause actual results to differ materially from those described in the forward-looking statements: the Company's history of losses and needs for additional capital to fund its operations and its inability to obtain additional capital on acceptable terms, or at all; the Company's ability to continue as a going concern; or maintain its current operations; uncertainties involving any strategic transaction the Company may decide to enter into as the result of its current efforts to explore new strategic alternatives; uncertainties of cash flows and inability to meet working capital needs; the Company's ability to obtain regulatory approvals; the Company's ability to obtain favorable pre-clinical and clinical trial results; the Company's technology may not be validated and its methods may not be accepted by the scientific community; difficulties enrolling patients in the Company's clinical trials; the ability to timely source adequate supply of FasL; risks resulting from unforeseen side effects; the Company's ability to establish and maintain strategic partnerships and other corporate collaborations; the scope of protection the Company is able to establish and maintain for intellectual property rights and its ability to operate its business without infringing the intellectual property rights of others; competitive companies, technologies and the Company's industry; unforeseen scientific difficulties may develop with the Company's technology; and the Company's ability to retain or attract key employees whose knowledge is essential to the development of its products. Any forward-looking statement in this press release speaks only as of the date of this press release. The Company undertakes no obligation to publicly update or review any forward-looking statement, whether as a result of new information, future developments or otherwise, except as may be required by any applicable securities laws. More detailed information about the risks and uncertainties affecting the Company is contained under the heading "Risk Factors" in Cellect Biotechnology Ltd.'s Annual Report on Form 20-F for the fiscal year ended December 31, 2020 filed with the U.S. Securities and Exchange Commission, or SEC, which is available on the SEC's website, http://www.sec.gov, and in the Company's periodic filings with the SEC.
ContactCellect Biotechnology Ltd.Eyal Leibovitz, Chief Financial Officerwww.cellect.co+972-9-974-1444Or
EVC Group LLC Michael Polyviou(732) email@example.com
Posted: August 5, 2021 at 2:33 am
CHICAGO & CAMBRIDGE, Mass.--(BUSINESS WIRE)--Exicure, Inc. (NASDAQ: XCUR), a pioneer in gene regulatory and immunotherapeutic drugs utilizing spherical nucleic acid (SNA) technology, today announced that CEO David Giljohann will present at the BTIG Virtual Biotechnology Conference on Monday, August 9, 2021 at 2:30pm ET. Exicure will also host 1x1 investor meetings during the conference.
BTIG hosted events are intended for prospective and existing BTIG clients only. To listen to the live event, please contact your BTIG representative with interest.
About Exicure, Inc.
Exicure, Inc. is a clinical-stage biotechnology company developing therapeutics for neurology, immuno-oncology, inflammatory diseases and other genetic disorders based on its proprietary Spherical Nucleic Acid, or SNA technology. Exicure believes that its proprietary SNA architecture has distinct chemical and biological properties that may provide advantages over other nucleic acid therapeutics and may have therapeutic potential to target diseases not typically addressed with other nucleic acid therapeutics. Exicure is in preclinical development of XCUR-FXN a lipid-nanoparticle SNAbased therapeutic candidate, for the intrathecal treatment of Friedreichs ataxia (FA). Exicures therapeutic candidate cavrotolimod (AST-008) is in a Phase 1b/2 clinical trial in patients with advanced solid tumors. Exicure is based in Chicago, IL and in Cambridge, MA.
View original post here:
Exicure, Inc. to Present at the BTIG Virtual Biotechnology Conference - Business Wire